novo nordisk cagrilintide Offers New Contender in Weight Management Novo Nordisk's experimental obesity drug

All three are research peptides labeled for research use only

The recommended starting point for finding UK trials is: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) the UK's public-facing portal for finding and joining clinical research studies ClinicalTrials.gov and the EU Clinical Trials Register international registries of ongoing studies, including the REDEFINE and TRIUMPH programmes Referral via a GP or specialist to a trial centre In the meantime, men with obesity or type 2 diabetes should be aware that NICE-approved treatments are already available and may offer meaningful clinical benefit: Semaglutide (Wegovy) is approved by NICE (TA875) for weight management in adults with a BMI 35 kg/m (or lower thresholds for certain ethnic groups) and at least one weight-related comorbidity, subject to specialist tier service criteria and duration requirements

Nandoe Tewarie RDS, Hurtado A, Ritfeld GJ, Rahiem ST, Wendell DF, Barroso MMS, et al

Pharmacokinetic studies have also not been conducted in people with hepatic impairment

Research References: Cagrilintide Amylin Analogue Research | Amylin Agonist Metabolic Studies Panda Peptide Quality Assurance: Every batch of Cagrilintide undergoes independent third-party HPLC and mass-spectrometry analysis before dispatch